Serum Ceramides as Prognostic Biomarkers of Large Thrombus Burden in Patients with STEMI: A Micro-Computed Tomography Study

Karagiannidis, Efstratios; Papazoglou, Αndreas S.; Stalikas, Nikolaos; Deda, Olga; Panteris, Eleftherios; Begou, Olga; Sofidis, Georgios; Moysidis, Dimitrios V.; Κάρτας, Αναστάσιος; Chatzinikolaou, Evangelia; Keklikoglou, Kleoniki; Bompoti, Andreana; Gika, Helen; Theodoridis, Georgios; Sianos, Georgios

doi:10.3390/jpm11020089

Cited by 14 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CorLipid study aimed to create an integrated panel of CAD-related biomarkers with the potential to support clinical decision making for the effective stratification and management of CAD patients [22]. Previous publication on a subset of STEMI patients enrolled in the CorLipid trial has revealed the prognostic value of serum ceramide levels on the occurrence of large thrombus burden [24]. Herein, we discuss the results from the quantitative profiling of 13 serum acylcarnitines as acquired by a state of the art LC-MS/MS method in 958 patients with CAD.…”

Section: Discussionmentioning

confidence: 99%

“…Herein, the investigation of 13 acylcarnitine circulating levels was performed upon their accurate determination by a newly developed LC-MS/MS method in patients admitted to AHEPA University Hospital for clinically indicated coronary angiography, and enrolled in the CorLipid study [22]. The determination of acylcarnitine levels was a part of a series of analyses of CVD-related biomarkers in the context of the CorLipid trial aiming to create a valuable panel for monitoring and predicting future cardiovascular events of patients with coronary artery disease (CAD) [23,24]. For the first time, the severity and the complexity of CAD, as described by the SYNTAX Score (SS), was correlated with circulating metabolic markers such as acylcarnitines, indicating that metabolomics might have brought a paradigm evolving metabolic research.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation of Serum Acylcarnitines with Clinical Presentation and Severity of Coronary Artery Disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

Recent studies support that acylcarnitines exert a significant role in cardiovascular disease development and progression. The aim of this metabolomics-based study was to investigate the association of serum acylcarnitine levels with coronary artery disease (CAD) severity, as assessed via SYNTAX Score. Within the context of the prospective CorLipid trial (NCT04580173), the levels of 13 circulating acylcarnitines were accurately determined through a newly developed HILIC-MS/MS method in 958 patients undergoing coronary angiography in the AHEPA University Hospital of Thessaloniki, Greece. Patients presenting with acute coronary syndrome had significantly lower median acylcarnitine C8, C10, C16, C18:1 and C18:2 values, compared to patients with chronic coronary syndrome (p = 0.012, 0.007, 0.018, 0.011 and <0.001, respectively). Among CAD subgroups, median C5 levels were significantly decreased in unstable angina compared to STEMI (p = 0.026), while median C10, C16, C18:1 and C18:2 levels were higher in stable angina compared to STEMI (p = 0.019 p = 0.012, p = 0.013 and p < 0.001, respectively). Moreover, median C2, C3, C4 and C8 levels were significantly elevated in patients with diabetes mellitus (p < 0.001, <0.001, 0.029 and 0.011, respectively). Moreover, short-chain acylcarnitine C2, C4, C5 and C6 levels were elevated in patients with heavier calcification and lower left ventricular ejection fraction (LVEF) % (all p-values less than 0.05). With regard to CAD severity, median C4 and C5 levels were elevated and C16 and C18:2 levels were reduced in the high CAD complexity group with SYNTAX score > 22 (p = 0.002, 0.024, 0.044 and 0.012, respectively), indicating a potential prognostic capability of those metabolites and of the ratio C4/C18:2 for the prediction of CAD severity. In conclusion, serum acylcarnitines could serve as clinically useful biomarkers leading to a more individualized management of patients with CAD, once further clinically oriented metabolomics-based studies provide similar evidence.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Correlation of Serum Acylcarnitines with Clinical Presentation and Severity of Coronary Artery Disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge, GESS is the first study yet to investigate the association of such a large number of candidate SNPs (228) with SYNTAX-score-based CAD complexity. To this end, GESS emerges as a part of a research project aspiring to complement traditional risk factor assessment with panels of significant metabolomic and genomic biomarkers [ 50 , 51 ]. The co-evaluation of novel risk factors and the complexity of CAD could significantly expand the concept of cardiovascular precision medicine.…”

Section: Discussionmentioning

confidence: 99%

The GEnetic Syntax Score: a genetic risk assessment implementation tool grading the complexity of coronary artery disease—rationale and design of the GESS study

Vizirianakis

Chatzopoulou

Papazoglou

et al. 2021

BMC Cardiovasc Disord

Self Cite

View full text Add to dashboard Cite

Background Coronary artery disease (CAD) remains one of the leading causes of mortality worldwide and is associated with multiple inherited and environmental risk factors. This study is designed to identify, design, and develop a panel of genetic markers that combined with clinical and angiographic information, will facilitate the creation of a personalized risk prediction algorithm (GEnetic Syntax Score—GESS). GESS score could be a reliable tool for predicting cardiovascular risk for future adverse events and for guiding therapeutic strategies. Methods GESS (ClinicalTrials.gov Identifier: NCT03150680) is a prospective, non-interventional clinical study designed to enroll 1080 consecutive patients with no prior history of coronary revascularization procedure, who undergo scheduled or emergency coronary angiography in AHEPA, University General Hospital of Thessaloniki. Next generation sequencing (NGS) technology will be used to genotype specific single-nucleotide polymorphisms (SNPs) across the genome of study participants, which were identified as clinically relevant to CAD after extensive bioinformatic analysis of literature-based SNPs. Enrichment analyses of Gene Ontology-Molecular Function, Reactome Pathways and Disease Ontology terms were also performed to identify the top 15 statistically significant terms and pathways. Furthermore, the SYNTAX score will be calculated for the assessment of CAD severity of all patients based on their angiographic findings. All patients will be followed-up for one-year, in order to record any major adverse cardiovascular events. Discussion A group of 228 SNPs was identified through bioinformatic and pharmacogenomic analysis to be involved in CAD through a wide range of pathways and was correlated with various laboratory and clinical parameters, along with the patients' response to clopidogrel and statin therapy. The annotation of these SNPs revealed 127 genes being affected by the presence of one or more SNPs. The first patient was enrolled in the study in February 2019 and enrollment is expected to be completed until June 2021. Hence, GESS is the first trial to date aspiring to develop a novel risk prediction algorithm, the GEnetic Syntax Score, able to identify patients at high risk for complex CAD based on their molecular signature profile and ultimately promote pharmacogenomics and precision medicine in routine clinical settings. Trial registration GESS trial registration: ClinicalTrials.gov Number: NCT03150680. Registered 12 May 2017- Prospectively registered, https://clinicaltrials.gov/ct2/show/NCT03150680.

show abstract

“…Nevertheless, QUEST-STEMI (Quantification of Extracted Thrombus Burden Characteristics and Association With Angiographic Outcomes in Patients With ST-Elevation Myocardial Infarction) is the first study of volumetric coronary thrombus assessment by micro-CT, and the observed scanning protocol could be used in other clinically-oriented trials in future to help to achieve personalised risk stratification-based care management, in accordance with thrombus burden encountered in each individual [ 92 ].…”

Section: Case Studiesmentioning

confidence: 99%

Micro-CT for Biological and Biomedical Studies: A Comparison of Imaging Techniques

et al. 2021

Self Cite

View full text Add to dashboard Cite

Several imaging techniques are used in biological and biomedical studies. Micro-computed tomography (micro-CT) is a non-destructive imaging technique that allows the rapid digitisation of internal and external structures of a sample in three dimensions and with great resolution. In this review, the strengths and weaknesses of some common imaging techniques applied in biological and biomedical fields, such as optical microscopy, confocal laser scanning microscopy, and scanning electron microscopy, are presented and compared with the micro-CT technique through five use cases. Finally, the ability of micro-CT to create non-destructively 3D anatomical and morphological data in sub-micron resolution and the necessity to develop complementary methods with other imaging techniques, in order to overcome limitations caused by each technique, is emphasised.

show abstract

Serum Ceramides as Prognostic Biomarkers of Large Thrombus Burden in Patients with STEMI: A Micro-Computed Tomography Study

Cited by 14 publications

References 27 publications

Correlation of Serum Acylcarnitines with Clinical Presentation and Severity of Coronary Artery Disease

Correlation of Serum Acylcarnitines with Clinical Presentation and Severity of Coronary Artery Disease

The GEnetic Syntax Score: a genetic risk assessment implementation tool grading the complexity of coronary artery disease—rationale and design of the GESS study

Micro-CT for Biological and Biomedical Studies: A Comparison of Imaging Techniques

Contact Info

Product

Resources

About